Watch the webcasts from our industry partners' Satellite Symposia.
11 Apr 2023
AiCME
Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
- Welcome and introductions
All Speakers - Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer
All Speakers - Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer
All Speakers - Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer
All Speakers - Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication
All Speakers - Questions and take-home learnings
All Speakers
12 Apr 2023
Gilead Sciences
BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer
- Welcome and introduction - Treatment landscape and emerging needs in metastatic breast cancer: Where are we today?
Wolfgang Janni - Optimal management in mTNBC: What have we learned from clinical practice?
Mafalda Oliveira - A new era of treatment for HR+/HER2- mBC: What do the clinical data tell us?
Komal Jhaveri - Closing remarks
Wolfgang Janni
Seagen
Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond
- Welcome and introductions
Andreas Schneeweiss - Evolving treatment landscape
Andreas Schneeweiss - Progression after T-DXd: What to do in 3L? (case-based discussion)
Joyce O'Shaughnessy - Optimizing outcomes for patients with CNS relapse (case-based discussion)
Barbara Pistilli - Q&A / Key takeaways
All Faculty
F. Hoffmann-La Roche
PI3King the right treatment for every patient with HR+ breast cancer
- Introduction
Sibylle Loibl - PI3K: A challenge to target but unmet need drives us onwards to success
Dejan Juric - PI3Kis: The clinical story so far and the next chapter
Sibylle Loibl - Q&A / discussion
All Faculty